Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia

Medicine and Dentistry

• Mortality 100%
• Infection 100%
• Antiinfective Agent 100%
• Disease Burden 100%
• Antibiotic Resistance 100%
• Hospital 41%
• Health Care Cost 33%
• Patient 33%
• Health 25%
• Pathogen 25%
• Death 25%
• Morbidity 16%
• Prematurity 16%
• Respiratory Tract Infection 16%
• Hospital Cost 16%
• Quality Adjusted Life Year 16%
• Emergency 8%
• Bacterium 8%
• Human 8%
• Surveillance 8%
• Pneumonia 8%
• Cohort Analysis 8%
• Methicillin Resistant Staphylococcus Aureus Infection 8%
• Antibiotic Therapy 8%
• Ceftazidime 8%
• Escherichia coli 8%
• Enterococcus 8%
• Bloodstream Infection 8%
• Staphylococcus Aureus 8%
• Urinary Tract 8%
• Hospital Infection 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Diseases 100%
• Infection 100%
• Mortality 100%
• Antiinfective Agent 100%
• Antimicrobial Resistance 100%
• Death 25%
• Infectious Agent 25%
• Morbidity 16%
• Prematurity 16%
• Respiratory Tract Infection 16%
• Pseudomonas aeruginosa 16%
• Human 8%
• Bacterium 8%
• Pneumonia 8%
• Methicillin Resistant Staphylococcus Aureus Infection 8%
• Ceftazidime 8%
• Antibiotics 8%
• Emergency 8%
• Animal 8%
• Bloodstream Infection 8%
• Hospital Infection 8%
• Community Acquired Infection 8%
• Escherichia coli 8%
• Enterococcus 8%
• Cohort Study 8%

Nursing and Health Professions

• Disease Burden 100%
• Mortality 100%
• Infection 100%
• Antiinfective Agent 100%
• Antimicrobial Resistance 100%
• Hospital 41%
• Death 25%
• Inpatient 16%
• Respiratory Tract Infection 16%
• Prematurity 16%
• Morbidity 16%
• Hospital Cost 16%
• Pneumonia 8%
• Emergency 8%
• Cohort Analysis 8%
• Bloodstream Infection 8%
• Antibiotic Therapy 8%
• Health Policy 8%